Veterinary Antibiotic Tilmicosin Phosphate Injection Tilmicosin Injection 30%

• Customization: Available
• Varieties: General Disease Prevention Medicine
• Component: Chemical Synthetic Drugs
• Type: The First Class
• Pharmacodynamic Influential Factors: Repeated Medication
• Storage Method: Prevent High or LowTemperature
• Transport Package: 100bottles/Carton
• Specification: tilmicosin injection 10% 20% 30%
• Trademark: SINOAH
• Origin: China
• HS Code: 3004101110
• Production Capacity: 10000000bottles/Month

Product Description

GMP factoru 10%, 25% & 30% Tilmicosin Phosphate Injection

 

Composition

Contains per ml.	:
Tilmicosin base	300 mg.
Solvents ad.	1 ml.

Specification: 25%,30%
 

Description :
Tilmicosin is a broad-spectrum semi-synthetic bactericidal macrolide antibiotic synthesized from tylosin. It has an antibacterial spectrum that is predominantly effective against Mycoplasma, Pasteurella and Haemophilus spp. and various Gram-positive organisms such as Corynebacterium spp. It is believed to affect bacterial protein synthesis through binding to 50S ribosomal subunits. Cross-resistance between tilmicosin and other macrolide antibiotics has been observed. Following oral administration, tilmicosin is excreted mainly via the bile into the faeces, with a small proportion being excreted via the urine.
 

Indication:
For first-line control and treatment of Bovine Respiratory Disease (BRD). Also used for the treatment of respiratory bacterial diseases in large ruminants, caused by Pasteurella miltocida, Mannheimia (Pasteurella) haemolytica, infection processes associated with Haemophilus somnus, Histophilus spp. etc.
 

Contra indications:
Hypersensitivity or resistance to tilmicosin.
Concurrent administration of other macrolides or lincosamides.
Administration to animals with an active microbial digestion or to equine or caprine species.
Parenteral administration, especially in porcine species.
Administration to poultry producing eggs for human consumption or to animals intended for breeding purposes.
During pregnancy and lactation, use only after a risk/benefit assessment by a veterinarian.
 

Side effects:
Occasionally, a transient reduction in water or (artificial) milk intake has been observed upon treatment with tilmicosin.